Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02269293
Title Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers
Recruitment Completed
Gender female
Phase Phase I
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center

endometrial cancer

fallopian tube cancer

peritoneum cancer

ovarian cancer

ovarian carcinosarcoma


Carboplatin + Paclitaxel + Selinexor

Age Groups: adult
Covered Countries USA

No variant requirements are available.